胆汁反流性胃炎 中国就医指南

Bile reflux gastritis is a chronic inflammatory condition of the gastric mucosa caused by the pathological backflow of bile and pancreatic secretions from the duodenum into the stomach. Unlike acid reflux, which involves gastric acid moving upward into the esophagus, bile reflux involves alkaline duodenal contents—including bile salts, lysolecithin, and pancreatic enzymes—entering the stomach lumen, disrupting the gastric mucosal barrier, impairing mucus-bicarbonate secretion, and triggering oxidative stress and neutrophil infiltration. This leads to erosive or non-erosive gastritis, often presenting with epigastric burning, postprandial fullness, nausea, bilious vomiting, and persistent upper abdominal discomfort unrelieved by standard proton pump inhibitors (PPIs). Pathogenesis centers on dysfunction of the pyloric sphincter—whether due to prior gastric surgery (e.g., gastrectomy, cholecystectomy, or Roux-en-Y procedures), chronic duodenogastric motility disorders, or structural abnormalities—and impaired gastric emptying, allowing retrograde flow. Epidemiologically, bile reflux gastritis is underdiagnosed but estimated to affect 15–25% of patients with chronic dyspepsia and up to 40–60% of those with post-surgical gastroparesis or biliary tract interventions. It is significantly more prevalent in adults aged 45–75 years, with no strong gender predilection. Key risk factors include prior upper gastrointestinal surgery (especially Billroth II gastrectomy), cholecystectomy, chronic pancreatitis, scleroderma-related gastroparesis, long-standing H. pylori-negative atrophic gastritis, and use of NSAIDs or calcium channel blockers that relax pyloric tone. Quality of life impact is substantial: patients frequently report fatigue, sleep disruption due to nocturnal symptoms, reduced work productivity, dietary restrictions (e.g., avoidance of fatty foods), anxiety about symptom recurrence, and diminished social engagement. Misdiagnosis as functional dyspepsia or GERD delays appropriate management, contributing to prolonged suffering and increased healthcare utilization. Without targeted intervention, bile reflux gastritis may progress to gastric metaplasia, intestinal metaplasia, and—rarely—dysplasia, underscoring the importance of timely endoscopic evaluation (including bile staining assessment and biopsy) and multimodal therapy.

# 胆汁反流性胃炎治疗方案与费用明细（消化内科）

一、非手术保守治疗（一线首选）

• •适用人群：轻中度症状、无幽门功能障碍、无Barrett食管或重度萎缩者
• •药物方案：

- 优化档（RMB 450–900/月）：UDCA + 替戈拉生（新型抑酸剂）+ 多潘立酮缓释片

• •检查费：胃镜+胆汁反流定量检测（RMB 800–1,200）、肝胆胰超声（RMB 200–350）、24h胆汁监测（RMB 1,800–2,500）

二、内镜微创干预（二线选择）

• •适用人群：药物抵抗、幽门松弛明显、胆汁反流量＞30%者
• •方案：内镜下幽门缩窄术（EPG）或胆汁引流支架置入
• •费用区间：术前评估（RMB 2,200–3,000）+ 手术费（RMB 12,000–22,000）+ 术后随访（RMB 600/次×3次）

三、外科根治性手术（严格指征）

• •适用人群：顽固性反流合并重度胃黏膜肠化/不典型增生，经≥12个月规范治疗无效者
• •术式：Roux-en-Y胃空肠吻合术（标准术式）
• •总费用：术前全套检查（RMB 4,500–6,200）+ 手术及住院（RMB 48,000–75,000）

四、复杂/耐药/并发症方案

• •合并重度萎缩性胃炎伴肠化：加用叶酸+维生素B12+定期胃镜活检（年均RMB 3,500–5,200）
• •合并胆囊结石/慢性胆囊炎：需同步腹腔镜胆囊切除（叠加费用RMB 15,000–28,000）

方案快速选择指南

• •预算＜3,000元/年：优选基础药物+生活方式管理
• •反复发作/中重度症状：升级至优化药物+24h胆汁监测（首年约RMB 8,000）
• •药物无效且内镜证实重度反流：EPG微创术（性价比最优）
• •癌前病变明确者：转外科评估Roux-en-Y手术